CTOs on the Move

SIGA Technologies

www.siga.com

 
SIGA Technologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.siga.com
  • 35 E 62nd St
    New York, NY USA 10065
  • Phone: 212.672.9100

Executives

Name Title Contact Details

Similar Companies

Iterion Therapeutics

Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics.

Beeken Biomedical

We are focused on the development, licensing and commercialization of wound care products. Its innovative Hemafiber Technology™ enables first responders and hospital patient care providers to rapidly control bleeding by using the NuStat products to es...

Mineralys Therapeutics

At Mineralys Therapeutics we aim to redefine hypertension diagnosis, management and treatment. We are driven to break the “trial and failure” approach to hypertension management and bring a personalized approach to the management of hypertension.

Promab Biotechnologies

Promab Biotechnologies is a Albany, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.